|Bid||3.69 x 1800|
|Ask||6.12 x 3100|
|Day's range||5.90 - 6.12|
|52-week range||3.46 - 10.88|
|Beta (5Y monthly)||1.32|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates.
At this time, I'd like to turn the call over to Courtney O'Konek, Senior Director of Corporate Communications and Investor Relations. With me today are Mark Enyedy, our President and CEO; Anna Berkenblit, our Chief Medical Officer; and Susan Altschuller, our CFO.
ImmunoGen (IMGN) delivered earnings and revenue surprises of 16.67% and -10.44%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?